At PMV, we believe that by specifically targeting each mutant p53 we can fundamentally disrupt the course of cancer. Our research and development efforts are dedicated to selectively targeting mutant p53, providing unique therapies for any patient whose tumor harbors these gene mutations.
Location: United States, New Jersey, Cranbury
Employees: 51-200
Total raised: $236M
Founded date: 2013
Investors 4
| Date | Name | Website |
| - | Avoro Capi... | avorocapit... |
| - | InterWest ... | interwest.... |
| - | RA Capital... | racap.com |
| - | OrbiMed | orbimed.co... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 04.08.2020 | Series D | $70M | - |
| 13.11.2019 | Series C | $62M | - |
| 27.02.2017 | Series B | $74M | - |
| 02.12.2014 | Series A | $30M | - |
Mentions in press and media 17
| Date | Title | Description |
| 10.05.2022 | PMV Pharmaceuticals Reports First Quarter 2022 Financial Results and Corporate Highlights | Oral presentation at 2022 ASCO annual meeting to highlight initial data from ongoing Phase 1/2 PYNNACLE study of PC14586 in patients with advanced solid tumors CRANBURY, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasd... |
| 04.08.2020 | PMV Pharma Closes $70M in Series D Financing | CRANBURY, NJ, PMV Pharmaceuticals announced the completion of a $70 million Series D financing round. >> Click here for more funding data on PMV Pharma >> To export PMV Pharma funding data to PDF and Excel, click here PMV... |
| 04.08.2020 | PMV Pharma nabs $70M for tumor suppressor programs | PMV Pharmaceuticals is topping up its coffers—just eight months after raising $62 million in its series C round, the cancer biotech is reeling in another $70 million. The capital will advance a suite of candidates targeting p53, a tumor-sup... |
| 03.08.2020 | PMV Pharma Closes $70 Million in Series D Financing | CRANBURY, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc., a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations, announced the completion... |
| 03.08.2020 | PMV Pharma nabs $70M for tumor suppressor programs | PMV Pharmaceuticals is topping up its coffers—just eight months after raising $62 million in its series C round, the cancer biotech is reeling in another $70 million. The capital will advance a suite of candidates targeting p53, a tumor-sup... |
| 13.11.2019 | PMV Pharma Secures $62 Million in Series C Financing To Develop Cancer Drugs Targeting p53 | - |
| 27.02.2017 | PMV Pharma Secures $74M in Series B | CRANBURY, NJ, Leader in the discovery and development of p53-targeted small molecule drugs for the treatment of cancer, announced the completion of a $74M Series B financing round. >> Click here for more funding data on PMV Pharma ... |
| 24.02.2017 | Term Sheet — Friday, February 24 | FRIDAY! Scoop: Roku is in advanced discussions to raise at least $200 million in new funding at a post-money valuation of approximately $1.5 billion, according to sources familiar with the situation. The company received a term sheet this w... |
| 22.02.2017 | PMV Pharmaceuticals Closes $74M Series B Funding | PMV Pharmaceuticals, Inc., a Cranbury, N.J.-based leader in the discovery and development of p53-targeted small molecule drugs for the treatment of cancer, completed a $74m Series B financing round. The round was led by Topspin Biotech Fund... |
| 22.02.2017 | Cancer startup PMV Pharma gains impressive $74M B round | New Jersey oncology biotech PMV Pharma has seen a healthy $74 million in funding from its Series B with help from InterWest Partners, Osage University Partners, Topspin Biotech Fund (which led this round), and its Series A lead investor Orb... |
Show more